SEARCH

SEARCH BY CITATION

References

  • 1
    Contreras F, Rivera M, Vásquez J, et al. Endothelial dysfunction in arterial hypertension. J Hum Hypertens. 2000;14(S1):S20S25.
  • 2
    Brunner H, Cockcroft JR, Deanfield J, et al. Endothelial function and dysfunction. Part II: association with cardiovascular risk factors and diseases. A statement by the working group on endothelins and endothelial factors of the European Society of Hypertension. J Hypertens. 2005;23:233246.
  • 3
    Dzau VJ. Theodore Cooper Lecture: tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis. Hypertension. 2001;37(4):10471052.
  • 4
    Burnier M. Angiotensin II type 1 receptor blockers. Circulation. 2001;103(6):904912.
  • 5
    Atlas S. The renin-angiotensin aldosterone system: pathophysiological role and pharmacologic inhibition. J Manag Care Pharm. 2007;13:S9S20.
  • 6
    Silverstein RL, Ram CV. Angiotensin-receptor blockers: benefits beyond lowering blood pressure. Cleve Clin J Med. 2005;72:825832.
  • 7
    Barreras A, Gurk-Turner C. Angiotensin II receptor blockers. Proc (Bayl Univ Med Cent). 2003;16:123126.
  • 8
    Joseph K, Kaplan AP. Formation of bradykinin: a major contributor to the innate inflammatory response. Adv Immunol. 2005;86:159208.
  • 9
    Tomaki M, Ichinose M, Miura M, et al. Angiotensin converting enzyme (ACE) inhibitor–induced cough and substance P. Thorax. 1996;51:199201.
  • 10
    Cugno M, Nussberger J, Cicardi M, et al. Bradykinin and the pathophysiology of angioedema. Int Immunopharmacol. 2003;3:311317.
  • 11
    Contreras F, de la Parte MA, Cabrera J, et al. Role of angiotensin II AT1 receptor blockers in the treatment of arterial hypertension. Am J Ther. 2003;10:401408.
  • 12
    Ruilope LM, Redon J, Schmieder R. Cardiovascular risk reduction by reversing endothelial dysfunction: ARBs, ACE inhibitors, or both? Expectations from the ONTARGET trial programme. Vasc Health Risk Manag. 2007;3:19.
  • 13
    Wagenaar LJ, Voors AA, Buikema H, et al. Angiotensin receptors in the cardiovascular system. Can J Cardiol. 2002;18:13311339.
  • 14
    Urata H, Kinoshita A, Misono KS, et al. Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart. J Biol Chem. 1990;265:2234822357.
  • 15
    Rigamonti E, Chinetti-Gbaguidi G, Staels B. Regulation of macrophage functions by PPARα, PPARγ, and LXRs in mice and men. Arterioscler Thromb Vasc Biol. 2008;28:10501059.
  • 16
    Erbe DV, Gartrell K, Zhang YL, et al. Molecular activation of PPARγ by angiotensin II type 1-receptor antagonists. Vascul Pharmacol. 2006;45:154162.
  • 17
    Kappert K, Tsuprykov O, Kaufmann J, et al. Chronic treatment with losartan results in sufficient serum levels of the metabolite EXP3179 for PPARγ activation. Hypertension. 2009;54:738743.
  • 18
    Storka A, Vojtassakova E, Mueller M, et al. Angiotensin inhibition stimulates PPARγ and the release of visfatin. Eur J Clin Invest. 2008;38:820826.
  • 19
    Blessing E, Preusch M, Kranzhöfer R, et al. Anti-atherosclerotic properties of telmisartan in advanced atherosclerotic lesions in apolipoprotein E deficient mice. Atherosclerosis. 2008;199:295303.
  • 20
    Nagy N, Melchior-Becker A, Fischer JW. Long-term treatment with the AT1-receptor antagonist telmisartan inhibits biglycan accumulation in the murine atherosclerosis. Basic Res Cardiol. 2010;105:2938.
  • 21
    Malmqvist K, Kahan T, Edner M, et al. Regression of left ventricular hypertrophy in human hypertension with irbesartan. J Hypertens. 2001;19:11671176.
  • 22
    Dahlöf B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:9951003.
  • 23
    Yusuf S, Teo K, Pogue J, et al. The ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:15471559.
  • 24
    Devereux RB, Dahlöf B, Gerdts E, et al. Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial. Circulation. 2004;110:14561462.
  • 25
    Strauss MH, Hall AS. Angiotensin receptor blockers may increase risk of myocardial infarction: unraveling the ARB-MI paradox. Circulation. 2006;114:838854.
  • 26
    Julius S, Kjeldsen Se, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomized trial. Lancet. 2004;363:20222031.
  • 27
    Yusuf S, Teo K, Anderson C, et al. The Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet. 2008;372:11741183.
  • 28
    Takahashi N, Ito M, Tanaka J, et al. Localization of the gene coding for myosin phosphatase, target subunit 1 (MYPT1) to human chromosome 12q15-q21. Genomics. 1997;44:150152.
  • 29
    Ararat E, Brozovich FV. Losartan decreases p42/44 MAPK signaling and preserves LZ+ MYPT1 expression. PLoS ONE. 2009;4:16.
  • 30
    Zhang W, Elimban V, Nijjar MS, et al. Role of mitogen-activated protein kinase in cardiac hypertrophy and heart failure. Exp Clin Cardiol. 2003;8:173183.
  • 31
    Chen PC, Ogut O, Rhee AY, et al. Captopril prevents myosin light chain phosphatase isoform switching to preserve normal cGMP-mediated vasodilatation. J Mol Cell Cardiol. 2004;41:488495.
  • 32
    Kohno T, Anzai T, Naito K, et al. Angiotensin-receptor blockade reduces border zone myocardial monocyte chemoattractant protein-1 expression and macrophage infiltration in post-infarction ventricular remodeling. Circ J. 2008;72:16851692.
  • 33
    Yu Y, Fukuda N, Yao EH, et al. Effects of an ARB on endothelial progenitor cell function and cardiovascular oxidation in hypertension. Am J Hypertens. 2008;21:7277.
  • 34
    Steinmetz M, Brouwers C, Nickenig G, et al. Synergistic effects of telmisartan and simvastatin on endothelial progenitor cells [abstract]. J Cell Mol Med. 2010;14:1645-1656.
  • 35
    Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003;349:18931906.
  • 36
    Barton M. Reversal of proteinuric renal disease and the emerging role of endothelin. Nat Clin Pract Nephrol. 2008;4:490501.
  • 37
    Nishiyama A, Nakagawa T, Kobori H, et al. Strict angiotensin blockade prevents the augmentation of intrarenal angiotensin II and podocyte abnormalities in type 2 diabetic rats with microalbuminuria. J Hypertens. 2008;26:18491859.
  • 38
    Liang XB, Ma LJ, Naito T, et al. Angiotensin type 1 receptor blocker restores podocyte potential to promote glomerular endothelial cell growth. J Am Soc Nephrol. 2006;17:18861895.
  • 39
    White WB. Update on the drug treatment of hypertension in patients with cardiovascular disease. Am J Med. 2005;118:695705.
  • 40
    Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851860.
  • 41
    Brenner BM, Cooper ME, de ZeeuwD, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861869.
  • 42
    Parving HH, Lehnert H, Bröchner-Mortensen J, et al. Irbesartan in Patients With Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001;345:870878.
  • 43
    Viberti G, Wheeldon NM. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation. 2002;106:672678.
  • 44
    Barnett AH, Bain SC, Bouter P, et al. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med. 2004;351:19521961.
  • 45
    Mann JF, Schmieder RE, McQueen M, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet. 2008;372:547553.
  • 46
    Mecca AP, O’Connor TE, Katovich MJ, et al. Candesartan pretreatment is cerebroprotective in a rat model of endothelin-1-induced middle cerebral artery occlusion. Exp Physiol. 2009;94:937946.
  • 47
    Kobayashi T, Kawamata T, Shibata N, et al. Angiotensin II type 1 receptor blocker telmisartan reduces cerebral infarct volume and periinfarct cytosolic phospholipase A2 level in experimental stroke. J Neurotrauma. 2009;26:23552364.
  • 48
    Munzenmaier DH, Green AS. Chronic angiotensin II AT1 receptor blockade increases cerebral cortical microvessel density. Am J Physiol Heart Circ Physiol. 2006;290:H512H516.
  • 49
    Papademetriou V, Farsang C, Elmfeldt D, et al. Stroke prevention with the angiotensin II type 1-receptor blocker candesartan in elderly patients with isolated systolic hypertension: the Study on Cognition and Prognosis in the Elderly (SCOPE). J Am Coll Cardiol. 2004;44:11751180.
  • 50
    Diener HC, Sacco RL, Yusuf Set al.; Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) study group. Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial: a double-blind, active and placebo-controlled study. Lancet Neurol. 2008;7:875884.
  • 51
    Pittas AG, Joseph NA, Greenberg AS. Adipocytokines and insulin resistance. J Clin Endocrinol Metab. 2004;89:447452.
  • 52
    Kurata A, Nishizawa H, Kihara S, et al. Blockade of angiotensin II type-1 receptor reduces oxidative stress in adipose tissue and ameliorates adipocytokine dysregulation. Kidney Int. 2006;70:17171724.
  • 53
    Lee MH, Song HK, Ko GJ, et al. Angiotensin receptor blockers improve insulin resistance in type 2 diabetic rats by modulating adipose tissue. Kidney Int. 2008;74:890900.
  • 54
    Andreozzi F, Laratta E, Sciacqua A, et al. Angiotensin II impairs the insulin signaling pathway promoting production of nitric oxide by inducing phosphorylation of insulin receptor substrate-1 on Ser312 and Ser616 in human umbilical vein endothelial cells. Circ Res. 2004;94:12111218.
  • 55
    NAVIGATOR Study Group, McMurray JJ, Holman RR, et al. Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med. 2010;362:14771490.
  • 56
    Nishimura H, Sanaka T, Tanihata Y, et al. Losartan elevates the serum high-molecular weight-adiponectin isoform and concurrently improves insulin sensitivity in patients with impaired glucose metabolism. Hypertens Res. 2008;31:16111618.
  • 57
    Georgescu EF, Ionescu R, Niculescu M, et al. Angiotensin-receptor blockers as therapy for mild-to-moderate hypertension-associated non-alcoholic steatohepatitis. World J Gastroenterol. 2009;15:942954.
  • 58
    Gillespie EL, White CM, Kardas M, et al. The impact of ACE inhibitors or angiotensin II type 1 receptor blockers on the development of new-onset type 2 diabetes. Diabetes Care. 2005;28:22612266.
  • 59
    Schmieder RE, Hilger KF, Schlaich MP, Schmidt BMW. Renin-angiotensin system and cardiovascular risk. Lancet. 2007;369:12081219.